Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Stelara shows promise for long-term management of ulcerative colitis

By Brian Buntz | July 9, 2021

Janssen Stelara Johnson & JohnsonJanssen’s (NYSE:JNJ) Stelara supported corticosteroid-free remission in about half of ulcerative colitis patients in a 152-week long-term extension UNIFI study.

At the end of the nearly three-year study, 55.2% of volunteers were in symptomatic remission. Of those patients, 96.4% were corticosteroid-free at week 152. Janssen, which is part of Johnson & Johnson, presented the data today at the Congress of the European Crohn’s and Colitis Organisation (ECCO).

Stelara (ustekinumab) enabled more than half of the patients in the trial to achieve remission without the need for steroids. That fact is one of the most critical findings in the recent data, said Dr. Jan Wehkamp, VP and gastroenterology disease area leader at Janssen.

While the human body naturally produces steroids, long-term use of corticosteroids leads to significant side effects in most people. They can lead to everything from high blood pressure, elevated blood sugar, glaucoma and other problems.

“While steroids are cheap and easy to access and are still the number one drug for patients with inflammatory bowel disease, there’s no controversy that long-term steroids use is really bad,” Wehkamp said. In prior roles, Wehkamp said he has come across patients with sleeping disorders, cosmetic side effects and osteoporosis from long-term steroid therapy. “I’ve seen patients who had broken bones because of a loss of bone density,” Wehkamp told Drug Discovery & Development in a recent interview.

“One of the most important treatment goals is to replace these bad drugs with drugs that have a much better safety profile,” he added.

Adverse events in the long-term extension study were similar for Stelara and placebo recipients.

Stelera Janssen Johnson & Johnson

Stelera is one of Janssen’s best-selling products. [Image courtesy of Janssen]

Stelara is a monoclonal antibody that selectively inhibits the interleukin (IL)-12 and IL-23 pathways. The drug won FDA approval for psoriasis in 2009 and psoriatic arthritis in 2013.

The FDA approved the drug for moderate to severe Crohn’s disease in 2016 and moderately to severely active ulcerative colitis in 2019.

Janssen reported two-year data from the UNIFI study in ulcerative colitis in 2019.

Stelara is currently one of the best-selling drugs on the market.

The most recent Stelara data are “very consistent with previous data,” Wehkamp said. “It’s not brand new that Stelara helped [ulcerative colitis] patients reduce their steroid use.” But the long-term data can inform patients and physicians. “Patients who get the disease don’t have a cure. They will still have the disease 60 years later,” Wehkamp added. “That’s why having these long-term data is so critical.”

 


Filed Under: Gastroenterology
Tagged With: corticosteroids, FDA, inflammation, inflammatory bowel disease, Janssen, Stelara, ulcerative colitis, UNIFI
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

One of C. difficile’s metabolic powers might be turning a toxin into a fuel
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly’s FDA approval for Omvoh close up: Nearly 90% of one-year responders maintained remission through two years
Lumen Bioscience
How an engineered algae-based biologic aims to break the annual $5B cycle of c. diff reinfection
DORA from Insilico Medicine
I gave an AI tool 25 minutes to write a science paper. Here’s what happened.
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE